NVAX
NOVAVAX INC
NASDAQ · Healthcare · Biotechnology · US
$10.82
−3.91%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- 421.06x
- P/E 2028E
- 39.40x
- P/S forward
- 4.51x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -9.36x
- Price / sales
- 4.31x
- Price / cash flow
- -45.18x
Enterprise value
- Enterprise value
- $1.4B
- EV / sales
- 3.29x
- EV / EBITDA
- -6.62x
- EV / EBIT
- -5.99x
- Market cap
- $1.8B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026